Literature DB >> 29952049

Empirical validation of the reverse parametric waiting time distribution and standard methods to estimate prescription durations for warfarin.

Julie Maria Thrane1, Henrik Støvring2, Maja Hellfritzsch1, Jesper Hallas1, Anton Pottegård1.   

Abstract

PURPOSE: In many prescription databases, the duration of treatment for the single prescription is not recorded. This study aimed to validate 2 different types of approaches for estimating prescription durations, using the oral anticoagulant warfarin as a case.
METHODS: The approaches undergoing empirical validation covered assumptions of a fixed daily intake of either 0.5 or 1.0 defined daily dose (DDD), as well as estimates based on the reverse parametric waiting time distribution (rWTD), with different sets of covariates. We converted estimates of prescription duration to daily dose and compared them to prescribed daily dose as recorded in a clinical registry (using Bland-Altman plots). Methods were compared based on their average prediction error (logarithmic scale) and their limit of agreement ratio (ratio of mean error ± 1.96 SD after transformation to original scale).
RESULTS: Estimates of daily doses were underestimated by 19% or overestimated by 62% when assumptions of 0.5 or 1.0 DDD were applied. The limit of agreement ratio was 6.721 for both assumptions. The rWTD-based approaches performed better when using the estimated mean value of the inter-arrival density, yielding on average negligible bias (relative difference of 0 to 2%) and with limit of agreement ratios decreasing upon additional covariate adjustment (from 6.857 with no adjustment to 4.036 with the fully adjusted model).
CONCLUSIONS: Comparing the different methods, the rWTD algorithm performed best and led to unbiased estimates of prescribed doses and thus prescription durations and reduced misclassification on the individual level upon inclusion of covariates.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Pharmacoepidemiology; defined daily dose; prescription duration; validation; waiting time distribution; warfarin

Mesh:

Substances:

Year:  2018        PMID: 29952049     DOI: 10.1002/pds.4581

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  3 in total

1.  Rationale and performances of a data-driven method for computing the duration of pharmacological prescriptions using secondary data sources.

Authors:  Laura Pazzagli; David Liang; Morten Andersen; Marie Linder; Abdul Rauf Khan; Maurizio Sessa
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.379

2.  A new likelihood model for analyses of pharmacoepidemiologic case-control studies which avoids decision rules for determining latent exposure status.

Authors:  Henrik Støvring; Anton Pottegård; Jesper Hallas
Journal:  BMC Med Res Methodol       Date:  2021-07-08       Impact factor: 4.615

Review 3.  Nordic Health Registry-Based Research: A Review of Health Care Systems and Key Registries.

Authors:  Kristina Laugesen; Jonas F Ludvigsson; Morten Schmidt; Mika Gissler; Unnur Anna Valdimarsdottir; Astrid Lunde; Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2021-07-19       Impact factor: 4.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.